ES2154287T3 - Procedimiento para modificar el crecimiento de los pelos y/o de los cabellos y composiciones utilizables a este efecto. - Google Patents

Procedimiento para modificar el crecimiento de los pelos y/o de los cabellos y composiciones utilizables a este efecto.

Info

Publication number
ES2154287T3
ES2154287T3 ES94402055T ES94402055T ES2154287T3 ES 2154287 T3 ES2154287 T3 ES 2154287T3 ES 94402055 T ES94402055 T ES 94402055T ES 94402055 T ES94402055 T ES 94402055T ES 2154287 T3 ES2154287 T3 ES 2154287T3
Authority
ES
Spain
Prior art keywords
hairs
growth
inhibitors
modify
compositions used
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94402055T
Other languages
English (en)
Inventor
Albert Duranton
Lacharriere Olivier De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9451783&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2154287(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by LOreal SA filed Critical LOreal SA
Application granted granted Critical
Publication of ES2154287T3 publication Critical patent/ES2154287T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/324—Boswellia, e.g. frankincense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A61K8/355—Quinones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A61K8/492—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9771—Ginkgophyta, e.g. Ginkgoaceae [Ginkgo family]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

LA INVENCION SE REFIERE A UN PROCESO DE TRATAMIENTO PARA MODIFICAR EL CRECIMIENTO DE VELLO Y/O CABELLO QUE CONSISTE ESENCIALMENTE EN ADMINISTRAR AL ORGANISMOS, POR VIA TOPICA Y/O SISTEMICA, SUSTANCIAS ELEGIDAS ENTRE LOS INHIBIDORES O LOS ESTIMULADORES DE LIPOXIGENASAS O DE CICLOOXIGENASAS, REALIZANDOSE DICHA ADMINISTRACION PREFERENTEMENTE EN COMBINACION CON EL APORTE (SIMULTANEO, SEPARADO O ESCALONADO EN EL TIEMPO) AL ORGANISMO, POR VIA TOPICA Y/O SISTEMICA, DE AL MENOS UN SUSTRATO, O UN PRECURSOR DE SUSTRATO, DE LIPOXIGENASAS Y DE CICLOOXIGENASAS. SEGUN LAS SUSTANCIAS ELEGIDAS, SE PUEDE FAVORECER EL CRECIMIENTO Y/O LIMITAR LA CAIDA DE DICHOS VELLOS Y/O DEL CABELLOS (UTILIZACION DE INHIBIDORES DE LIPOXIGENASAS Y/O DE ESTIMULADORES DE CICLOOXIGENASAS) BIEN, AL CONTRARIO DISMINUIR O IMPEDIR EL CRECIMIENTO DE ESTOS ULTIMOS (UTILIZACION DE ESTIMULADORES DE LIPOXIGENASAS Y/O INHIBIDORES DE CICLOOXIGENAS). LA INVENCION SE REFIERE TAMBIEN A DIVERSAS COMPOSICIONES UTILIZABLES PARA LA APLICACION DELPROCESO.
ES94402055T 1993-10-13 1994-09-14 Procedimiento para modificar el crecimiento de los pelos y/o de los cabellos y composiciones utilizables a este efecto. Expired - Lifetime ES2154287T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9312178A FR2711060B1 (fr) 1993-10-13 1993-10-13 Procédé pour modifier la pousse des poils et/ou des cheveux et compositions utilisables à cet effet.

Publications (1)

Publication Number Publication Date
ES2154287T3 true ES2154287T3 (es) 2001-04-01

Family

ID=9451783

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94402055T Expired - Lifetime ES2154287T3 (es) 1993-10-13 1994-09-14 Procedimiento para modificar el crecimiento de los pelos y/o de los cabellos y composiciones utilizables a este efecto.

Country Status (7)

Country Link
US (2) US6465421B1 (es)
EP (1) EP0648488B1 (es)
JP (1) JP2883821B2 (es)
CA (1) CA2132507C (es)
DE (1) DE69426351T2 (es)
ES (1) ES2154287T3 (es)
FR (1) FR2711060B1 (es)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248751B1 (en) 1993-05-28 2001-06-19 Gurpreet S. Ahluwalia Inhibition of hair growth
US6414017B2 (en) 1993-05-28 2002-07-02 The Gillette Company Inhibition of hair growth
US6239170B1 (en) 1993-05-28 2001-05-29 Gurpreet S. Ahluwalia Inhibition of hair growth
US5554608A (en) * 1994-09-28 1996-09-10 Ahluwalia; Gurpreet S. Inhibition of hair growth
FR2732597B1 (fr) * 1995-04-05 1997-05-16 Oreal Utilisation dans une composition en tant qu'activateur et/ou stabilisateur de cyclooxygenase d'au moins un derive de pyrimidine substitue en 6
FR2747568B1 (fr) * 1996-04-17 1999-09-17 Oreal Utilisation d'au moins un inhibiteur de lipoxygenase et d'au moins un inhibiteur de cyclo-oxygenase pour modifier la pousse des poils et/ou des cheveux
FR2753375B1 (fr) * 1996-09-17 1999-12-03 Oreal Utilisation dans une composition cosmetique ou pour la preparation d'un medicament d'au moins un inhibiteur de sulfotransferases
DE69823852T2 (de) * 1997-02-04 2005-05-19 Johnstone, Murray A., Seattle Verfahren zur förderung des haarwuchses und entwicklung des haarsystems
AU1289899A (en) * 1997-10-31 1999-05-24 Arch Development Corporation Methods and compositions for regulation of 5-alpha reductase activity
US5958946A (en) * 1998-01-20 1999-09-28 Styczynski; Peter Modulation of hair growth
AUPP307698A0 (en) * 1998-04-20 1998-05-14 Miller, Matthew Depilatory compositions comprising chelating agents
FR2781147B1 (fr) 1998-07-20 2000-09-15 Oreal Compositions pour la teinture des fibres keratiniques contenant des derives de 3-amino pyrazolines a titre de coupleur, procede de teinture et kit de teinture
ES2239846T5 (es) * 1998-07-30 2011-03-04 The Government Of The United States Of America, As Repres. By The Secretary Of Health And Human Services, Nat. Inst. Of Health Mejora de la curación de heridas mediante la timosina beta-4.
JP2002528540A (ja) * 1998-10-30 2002-09-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング ルテオリン及びルテオリン誘導体の製造方法
WO2000051980A1 (en) 1999-03-05 2000-09-08 The Procter & Gamble Company C16 unsaturated fp-selective prostaglandins analogs
FR2791671B1 (fr) 1999-04-01 2001-05-11 Oreal Nouveaux composes derives d'esters d'acide benzoique, composition les comprenant et utilisation
US6933104B1 (en) 1999-04-23 2005-08-23 Shiva Biomedical, Llc Diagnosis and treatment of human kidney diseases
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
DE60022892T2 (de) * 1999-10-21 2006-07-13 Kao Corp. Verfahren zur Enthaarung
MXPA02004010A (es) * 1999-10-26 2002-10-23 Univ Texas Southwestern Med Ct Metodos para tratamiento de perdida capilar que consisten en administrar compuesto de indolina.
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
FR2812191B1 (fr) * 2000-07-28 2003-10-17 Oreal Utilisation d'agonistes du recepteur des prostaglandines e2 (ep-3) pour attenuer, diminuer ou stopper la pousse des cheveux et des poils dans des preparations cosmetiques
FR2812192B1 (fr) * 2000-07-28 2003-01-31 Oreal Utilisation d'antagonistes de recepteur des prostaglandines ep-3 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils
FR2812193B1 (fr) * 2000-07-28 2003-10-24 Oreal Utilisation d'antagoniste des recepteurs des prostaglandines ep-2 et/ou ep-4 pour attenuer, diminuer ou stopper la pousse des cheveux et des poils dans des preparations cosmetiques
FR2812190B1 (fr) * 2000-07-28 2003-01-31 Oreal Utilisation d'agonistes non prostanoiques des recepteurs des prostaglandines ep-2 et/ou ep-4 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils
FR2835525B1 (fr) 2002-02-04 2006-02-10 Oreal Nouveaux composes, compositions les comprenant et leur utilisation pour favoriser la desquamation
US20030224024A1 (en) * 2002-02-04 2003-12-04 Jean-Luc Leveque Compositions comprising cyclopentane derivatives and their use
US8603502B2 (en) 2002-02-04 2013-12-10 L'oreal S.A. Compositions comprising jasmonic acid derivatives and use of these derivatives
WO2003077860A2 (en) * 2002-03-13 2003-09-25 Biophysica, Inc. BOSWELLIN COMPOSITIONS ENHANCED WITH 3-β-ACETYL-11-KETO-β-BOSWELLIC ACID (“AKBA”), INDUSTRIAL MANUFACTURE AND THEIR USES
US20050176822A1 (en) * 2002-03-28 2005-08-11 Naoto Hanyu Phenylacetonitrile derivatives and hair tonics and external preparations for skin containing the derivatives
FR2844454B1 (fr) * 2002-09-12 2006-05-19 Marc Schwaller Composition comprenant en association au moins une huile de courge et au moins une huile de bourrache,son utilisation comme medicament, comme agent dermatologique ou dermato-cosmetique
AU2003293977A1 (en) * 2002-10-16 2004-05-04 L'oreal Cosmetic composition for preventing and/or correcting the functional disorders of the pilo-sebaceous unit of mammals
TW200407172A (en) * 2002-10-17 2004-05-16 Unilever Nv Scalp treatment
US7326717B2 (en) 2003-05-06 2008-02-05 L'oreal Pyrimidine n-oxide compounds for stimulating the growth of keratin fibers and/or reducing loss thereof
KR100579710B1 (ko) * 2003-09-16 2006-05-15 학교법인조선대학교 은행잎에서 분리한 비듬치료 및 탈모방지용 샴푸 조성물
EP1684774B1 (en) * 2003-11-05 2012-08-29 Osteoscreen, Inc. Stimulation of hair growth by isoginkgetin
EP1732500B1 (en) 2004-01-07 2018-11-21 E-L Management Corporation Cosmetic composition and method for retarding hair growth
US20050186231A1 (en) * 2004-02-19 2005-08-25 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Stabilization with substituted ureas against color degradation of personal care products
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
US7666442B2 (en) * 2004-08-31 2010-02-23 Tracie Martyn International, Llc Topical compositions comprising benfotiamine and pyridoxamine
WO2006053184A2 (en) * 2004-11-10 2006-05-18 The Trustees Of Columbia University In The City Of New York Methods for treating or preventing a vascular disease
FR2879444B1 (fr) * 2004-12-22 2007-05-18 Oreal Utilisation d'un compose capable d'augmenter le taux de glutathion dans les melanocytes pour le traitement de la canitie
US20060193804A1 (en) * 2005-02-24 2006-08-31 L'oreal Haircare use of cyclic amine derivatives
EP2236126A1 (en) * 2005-03-12 2010-10-06 Unilever PLC Hair and/or Scalp Care Compositions Incorporating Isophaseollin
RU2389487C2 (ru) * 2005-03-12 2010-05-20 Унилевер Нв Композиции для ухода за волосами и/или кожей головы, включающие флавоноидные соединения
WO2006097193A1 (en) * 2005-03-12 2006-09-21 Unilever Plc Hair and/or scalp care compositions incorporating amino-oxo-indole-ylidene compounds
US11039997B2 (en) 2005-12-27 2021-06-22 Ruth-Maria Korth Cosmetic, dermatic, protective compositions comprising phospholipids, lecithins with peptides and at least one acetylating compound
EP2077819A4 (en) 2006-09-28 2011-05-25 Follica Inc PROCESSES, KITS AND COMPOSITIONS FOR PRODUCING NEW HAIRFOLLICLES AND GROWING HAIR
FR2920309B1 (fr) 2007-08-28 2010-05-28 Galderma Res & Dev Utilisation de travoprost pour traiter la chute des cheveux
US8067470B2 (en) * 2008-02-01 2011-11-29 Mcdaniel William Robert Linoleic acid preparations for the topical treatment of male and female pattern androgenetic alopecia, age-related alopecia, and keratosis pilaris
FR2929117B1 (fr) 2008-03-28 2010-05-07 Oreal Utilisation de l'association du 2,4-diaminopyrimidine 3-n-oxyde et du madecassosside et/ou du terminoloside pour induire et/ou stimuler la croissance de ces fibres keratiniques humaines et/ou freiner leur chute
WO2010013182A1 (en) 2008-07-29 2010-02-04 L'oreal Cosmetic use of microorganism(s) for the treatment of scalp disorders
EP2168570B1 (en) 2008-09-30 2013-12-25 Symrise AG Extracts of isochrysis sp.
MX2011004824A (es) 2008-11-07 2012-01-12 Triact Therapeutics Inc Uso de derivados de butano catecólico en terapia contra el cáncer.
WO2010064203A1 (en) 2008-12-02 2010-06-10 L'oreal Combination of reduced glutathione and amino acids for improving the quality of the hair in women
FR2949052B1 (fr) 2009-08-13 2015-03-27 Oreal Procede de traitement cosmetique du cuir chevelu.
FR2951938B1 (fr) 2009-10-30 2012-01-06 Oreal Utilisation d'un extrait de punica granatum pour lutter contre la canitie
ATE537808T1 (de) 2010-03-26 2012-01-15 Procter & Gamble Verfahren zur depilation und depilierausrüstung
US20140093466A1 (en) 2012-10-02 2014-04-03 The Procter & Gamble Company Hair care compositions and methods of use
WO2013158649A1 (en) 2012-04-16 2013-10-24 Case Western Reserve University Compositions and methods of modulating 15-pgdh activity
US9834575B2 (en) 2013-02-26 2017-12-05 Triact Therapeutics, Inc. Cancer therapy
US10123966B2 (en) 2013-05-16 2018-11-13 The Procter And Gamble Company Hair thickening compositions and methods of use
CA2923667A1 (en) 2013-09-09 2015-03-12 Triact Therapeutics, Inc. Cancer therapy
US9789116B2 (en) 2013-10-15 2017-10-17 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
TR201808036T4 (tr) * 2014-05-06 2018-06-21 Fidia Farm Spa Di homo gama linolenik asit (dgla) içeren lipozomlar, bunları içeren formülasyonlar ve bunların kullanımı.
WO2018102552A1 (en) 2016-11-30 2018-06-07 Case Western Reserve University Combinations of 15-pgdh inhibitors with corcosteroids and/or tnf inhibitors and uses thereof
US11718589B2 (en) 2017-02-06 2023-08-08 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase
KR102921276B1 (ko) 2018-11-21 2026-02-03 케이스 웨스턴 리저브 유니버시티 단쇄 데히드로게나아제 활성을 조절하는 조성물 및 방법
MX2022014637A (es) 2020-05-20 2023-03-03 Rodeo Therapeutics Corp Composiciones y metodos para modular la actividad de deshidrogenasas de cadena corta.

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1371101A (en) * 1971-02-03 1974-10-23 Unilever Ltd Production of detergent compositions
FR2380775A1 (fr) 1977-02-22 1978-09-15 Sederma Sarl Composition " apres-epilation " favorisant un ralentissement progressif de la repousse des poils
US5002941A (en) 1985-12-12 1991-03-26 Smithkline Beecham Corporation Pyrrolo(1,2-a)imidazole and imidazo(1,2-a)pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors
US4686231A (en) 1985-12-12 1987-08-11 Smithkline Beckman Corporation Inhibition of 5-lipoxygenase products
US4847270A (en) 1985-12-12 1989-07-11 Smithkline Beckman Corporation Inhibition of the 5-lipoxygenase pathway utilizing certain 2,2'-alkyldiyl bis(thio)bis-imidazoles and derivatives
GB8630721D0 (en) * 1986-12-23 1987-02-04 Unilever Plc Cosmetic compositions
JPH085788B2 (ja) * 1987-10-08 1996-01-24 花王株式会社 ５α−リダクターゼ阻害剤
LU87308A1 (fr) * 1988-08-01 1990-03-13 Oreal Nouveaux derives de diamino-2,4 pyrimidine oxyde-3 et leur utilisation pour le traitement et la prevention de la chute des cheveux
US5037655A (en) * 1990-04-18 1991-08-06 Giovanoni Richard L Method of stabilizing tretinoin
GB9014221D0 (en) 1990-06-26 1990-08-15 Janssen Pharmaceutica Nv Method of treating alopecia
US5082661A (en) * 1990-09-26 1992-01-21 Elizabeth Arden Co., Division Of Conopco, Inc. Odorless cosmetic compositions in gelatin capsules
US5514667A (en) * 1990-11-05 1996-05-07 Arthropharm Pty. Limited Method for topical treatment of herpes infections
JPH05238950A (ja) * 1991-04-22 1993-09-17 Sanwa Kagaku Kenkyusho Co Ltd 易吸収性ｖｉｐ製剤
US6239170B1 (en) 1993-05-28 2001-05-29 Gurpreet S. Ahluwalia Inhibition of hair growth
US6248751B1 (en) 1993-05-28 2001-06-19 Gurpreet S. Ahluwalia Inhibition of hair growth
US6515014B2 (en) * 1995-06-02 2003-02-04 G. D. Searle & Co. Thiophene substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
JP4370315B2 (ja) * 2006-08-11 2009-11-25 栄通信工業株式会社 スイッチ用カム機構

Also Published As

Publication number Publication date
US6465421B1 (en) 2002-10-15
CA2132507C (fr) 2007-02-06
JPH07238037A (ja) 1995-09-12
EP0648488A1 (fr) 1995-04-19
EP0648488B1 (fr) 2000-11-29
CA2132507A1 (fr) 1995-04-14
DE69426351T2 (de) 2001-04-05
FR2711060A1 (fr) 1995-04-21
US20030064929A1 (en) 2003-04-03
JP2883821B2 (ja) 1999-04-19
FR2711060B1 (fr) 1995-11-17
DE69426351D1 (de) 2001-01-04

Similar Documents

Publication Publication Date Title
ES2154287T3 (es) Procedimiento para modificar el crecimiento de los pelos y/o de los cabellos y composiciones utilizables a este efecto.
ATE207342T1 (de) Gegen hautalterung wirksame stoffe oder wirkstoffkombinationen und zubereitungen
BR9406893A (pt) Emprego de nona- e decapeptideos para a preparação de um medicamento para o combate da aids
BR9507506A (pt) Processo para exterminar uma célula processo para tratamento de càncer composição e kit terapéutico
ES2178048T3 (es) Uso de rifaximina como medicamento para el tratamiento de diarrea por criptosporidiosis.
BR9710768A (pt) Composto composi-Æo e processos para tratamento de infec-{es bacterianas em um mamifero hospedeiro com necessidade de tal tratamento e para prepara-Æo de 6-0-metileritromicina forma i
ATE177640T1 (de) Pharmazeutische zusammensetzung zur wund-, narben- und keloidbehandlung
ATE30575T1 (de) Stabilisierter aktivierter sauerstoff und arzneimittel, die diesen stabilisierten aktivierten sauerstoff enthalten.
BRPI0517481A (pt) método para tratar, controlar ou evitar uma doença ou distúrbio parasìtico protozoário, e, composição farmacêutica
ES2057124T3 (es) Producto terapeutico para el tratamiento de estados peri- o post-menopausicos.
DK0723444T3 (da) Levobupivacain, som er egnet til behandling af kronisk smerte
SE9701161D0 (sv) New use I
AR006401A1 (es) Compuestos de pirrolopirrolona, una composicion farmaceutica que los contiene, su uso en la fabricacion de un medicamento y en terapia, procesospara su preparación y compuestos intermediarios para dichos procesos.
NZ505742A (en) Compositions containing aminobiguanides with antimicrobial activity used to treat contact lenses
ATE275966T1 (de) Activin stimulator enthaltende pharmazeutische zusammensetzung
AR020660A1 (es) Composiciones antibioticas para el tratamiento de ojos, oidos y nariz
BR9712141A (pt) Aplicação de 1-hifróxi-2-piridonas para tratamento de infecções cutâneas.
ITMI922331A1 (it) Uso di paratormone, suoi frammenti biologicamente attivi e peptidi correlati, per la preparazione di composizioni farmaceutiche utili nella prevenzione e terapia dell'aborto e del parto pretermine ed in generale per il trattamento della gestazione
PT90085A (pt) Processo para a preparacao de composicoes farmaceuticas contendo um complexo organico de ouro para aplicacao topica
ES2172171T3 (es) Medicamento, que contiene yohimbina y arginina, para el tratamiento de disfunciones erectiles.
FI962550A0 (fi) Deuterisoidut vaikuttavat aineet transdermaalisessa käyttötarkoituksessa
BR0311371A (pt) Composições para uso terapêutico compreendendo uma vitamina, um sal de metal e insulina ou um hormÈnio de crescimento
MX9203405A (es) Compuestos activos para usarse en el tratamiento de tumores.
RU94041028A (ru) Применение производных мелатонина для лечения десинхронизационных нарушений, фармацевтическая композиция
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 648488

Country of ref document: ES